Ethics Approval Secured for Phase 1A Clinical Trial
Filed with ASX · · 3 pages · English
Story so far
Earlier from Patrys
- Investor Presentation - TechKnow Invest Roadshow
- Appendix 4C - Quarterly - 30 June 2026
- Patrys Secures 50% Revenue Share in IP Commercialisation
- Patrys advances RLS-2202 toward Phase 1 Clinical Trial
- Appendix 4C - Quarterly - 31 March 2026
Later from Patrys
- PAB Establishes Clinical Advisory Committee
- First Participants Dosed in RLS-2202 Phase 1A Clinical Trial
- Appendix 4E Variance Report
- Investor Webinar
- Investor Presentation
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys